Suchergebnisse - "Radj, Gervais"

PubPharm (9)

1

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies : A multicentre phase II open-label non-randomised study GFPC 06-2018

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Bylicki, O. | Tomasini, P. | Radj, G. | +20

2

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives

in: Cancers | 2022

von Mathieu Césaire | Juliette Montanari | Hubert Curcio | +5

3

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

in: Therapeutic Advances in Medical Oncology | 2021

von Isabelle Monnet | Alain Vergnenègre | Gilles Robinet | +16

4

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors

in: Journal for ImmunoTherapy of Cancer | 2020

von Charles Dolladille | Joachim Alexandre | Radj Gervais | +7

5

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study

in: Therapeutic Advances in Medical Oncology | 2020

von Dominique Arpin | Marie-Christine Charpentier | Marie Bernardi | +23

6

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

in: BMC Cancer | 2019

von Manon Kissel | Isabelle Martel-Lafay | Justine Lequesne | +11

7

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

in: Cancer Medicine | 2018

von Paul Lesueur | Alexandre Escande | Juliette Thariat | +9

8

Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test

in: Clinical Medicine Insights: Oncology | 2014

von Benoît Dupont | Delphine Mariotte | Cristian Moldovan | +4

9

Case Report about Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test

in: Clinical Medicine Insights: Oncology | 2014

von Benoît Dupont | Delphine Mariotte | Cristian Moldovan | +4

1
[1]